Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | PLK1 | P53350 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6918970 | 0.82 | L3MBTL1 (0.53) | L3MBTL1KMT2ARAB9AHDAC2HDAC8 | |
| SCHEMBL28192657 | 0.80 | L3MBTL1 (0.55) | L3MBTL1KMT2ARAB9ASMN1; SMN2EPHX2 | |
| SCHEMBL12561259 | 0.79 | L3MBTL1 (0.59) | L3MBTL1KMT2ARAB9ASMN1; SMN2EPHX2 | |
| SCHEMBL13701751 | 0.79 | KMT2A (0.48) | L3MBTL1KMT2ARAB9ASMN1; SMN2EPHX2 | |
| SCHEMBL12376722 | 0.79 | SMN1; SMN2 (0.59) | L3MBTL1KMT2ARAB9ASMN1; SMN2EPHX2 | |
| SCHEMBL657937 | 0.77 | POLB (0.47) | L3MBTL1KMT2ARAB9ASMN1; SMN2EPHX2 | |
| SCHEMBL13702359 | 0.77 | CRBN (0.56) | KMT2AHDAC8HDAC6MEN1POLB | |
| SCHEMBL246545 | 0.76 | POLB (0.73) | KMT2ARAB9ALMNAMEN1POLB | |
| SCHEMBL17184616 | 0.76 | POLB (0.44) | L3MBTL1KMT2ARAB9ASMN1; SMN2EPHX2 | |
| SCHEMBL29781378 | 0.75 | LMNA (0.49) | L3MBTL1KMT2ARAB9ASMN1; SMN2EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 158 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4604968-A1 | ENHANCED NAD+ COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME | Bionadrx Holdings, Inc. (US) | 2025-08-27 | — | — | EP | claimed |
| WO-2024254556-A9 | BACTERIAL COMPOSITIONS FOR METABOLIZING UREMIC TOXINS | ATOSSA THERAPEUTICS, INC. (US) | 2025-01-30 | — | — | WO | claimed |
| WO-2024254556-A1 | BACTERIAL COMPOSITIONS FOR METABOLIZING UREMIC TOXINS | ATOSSA THERAPEUTICS, INC. (US) | 2024-12-12 | — | — | WO | claimed |
| WO-2024086312-A1 | ENHANCED NAD+ COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME | BIONADRX HOLDINGS, INC. DBA BRYLEOS (US) | 2024-04-25 | — | — | WO | claimed |
| US-20230243752-A1 | SYSTEM AND METHOD FOR MONITORING THE HEALTH OF DIALYSIS PATIENTS | VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. | 2023-08-03 | — | — | US | claimed |
| WO-2023114656-A1 | METHODS FOR TREATING AND PREVENTING DISEASES AND DISORDER THROUGH MODULATION OF NAD | MARK PAUL (US) | 2023-06-22 | — | — | WO | claimed |
| US-11674903-B2 | System and method for monitoring the health of dialysis patients | VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. (US) | 2023-06-13 | — | — | US | claimed |
| EP-3490982-A1 | PHARMACEUTICAL COMPOUNDS | Almac Discovery Limited (GB) | 2019-06-05 | — | — | EP | claimed |
| WO-2018191771-A1 | DETECTION AND TREATMENT OF CONGENITAL MALFORMATIONS | VICTOR CHANG CARDIAC RESEARCH INSTITUTE (AU) | 2018-10-25 | — | — | WO | claimed |
| WO-2018020242-A1 | PHARMACEUTICAL COMPOUNDS | ALMAC DISCOVERY LIMITED (GB) | 2018-02-01 | — | — | WO | claimed |
| EP-3151665-A1 | METHODS AND SYSTEMS FOR DETERMINING AUTISM SPECTRUM DISORDER RISK | Laboratory Corporation of America Holdings (US) | 2017-04-12 | — | — | EP | claimed |
| US-20170045455-A1 | SYSTEM AND METHOD FOR MONITORING THE HEALTH OF DIALYSIS PATIENTS | VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. (US) | 2017-02-16 | — | — | US | claimed |
| WO-2015164620-A1 | SYSTEM AND METHOD FOR MONITORING THE HEALTH OF DIALYSIS PATIENTS | ROBERTSON JOHN L (US) | 2015-10-29 | — | — | WO | claimed |
| WO-2015157601-A1 | METHODS AND SYSTEMS FOR DETERMINING AUTISM SPECTRUM DISORDER RISK | SYNAPDX CORPORATION (US) | 2015-10-15 | — | — | WO | claimed |
| US-9072732-B2 | Indication for use of niacin (nicotinic acid) for treatment and reversal of fatty liver disease | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-07-07 | — | — | US | claimed |
| WO-2014004539-A1 | METABOLOMICS IN PNEUMONIA AND SEPSIS | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2014-01-03 | — | — | WO | claimed |
| WO-2006024545-A1 | FUSED BICYCLIC NATURAL COMPOUNDS AND THEIR USE AS INHIBITORS OF PARP AND PARP-MEDIATED INFLAMMATORY PROCESSES | STICHTING VOOR DE TECHNISCHE WETENSCHAPPEN (NL) | 2006-03-09 | — | — | WO | claimed |
| US-6143770-A | MIXTURES OF TOCOTRIENOL AND NICOTINIC ACID | LIPOGENICS, INC. (US) | 2000-11-07 | — | — | US | claimed |
| EP-4117629-B1 | COMPOSITIONS AND MEDICAL USE OF NALOXONE | PURDUE PHARMA LP (US) | 2026-04-15 | — | — | EP | disclosed |
| WO-1992020816-A1 | DETERMINATION OF PRODRUGS METABOLIZABLE BY THE LIVER AND THERAPEUTIC USE THEREOF | YALE UNIVERSITY (US) | 1992-11-26 | — | — | WO | disclosed |